Xencor, Inc. - Common Stock (NQ:XNCR)

25.27 +0.43 (+1.71%)

Delayed Quote Updated: 11:22 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Stocks That Hit 52-Week Lows On Friday ↗

March 04, 2022

On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Xencor: Q4 Earnings Insights ↗

February 23, 2022

Xencor (NASDAQ:XNCR) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor...

Via Benzinga

Xencor: Q3 Earnings Insights ↗

November 08, 2021

Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Xencor their...

Via Benzinga

Xencor Reports Fourth Quarter and Full Year 2021 Financial Results

February 23, 2022

From Xencor, Inc.

Via Business Wire

Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022

February 16, 2022

From Xencor, Inc.

Via Business Wire

Xencor to Present at Upcoming Investor Conferences

February 02, 2022

From Xencor, Inc.

Via Business Wire

Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

January 11, 2022

From Xencor, Inc.

Via Business Wire

Earnings Scheduled For February 23, 2022 ↗

February 23, 2022

Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...

Via Benzinga

Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference

January 06, 2022

From Xencor, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 ↗

December 15, 2021

Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:

Via Benzinga

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

December 12, 2021

From Xencor, Inc.

Via Business Wire

Week In Review: Shanghai's Zenas Acquires CD19 Antibody From Xenco In $480 Million Deal ↗

November 27, 2021

In a $480 million deal, Zenas acquired global rights to a bifunctional antibody from Xencor that targets CD19. Instead of an upfront payment, Zenas will issue a warrant granting Xencor the right to...

Via Talk Markets

Pfizer Sues Former Employee For Stealing Confidential Info On Its Megablockbuster COVID-19 Vaccine ↗

November 24, 2021

Pfizer Inc (NYSE: PFE) has sued its former associate director of clinical statistics in a California court to get a handle on allegedly stolen information. The Company's...

Via Benzinga

Topics Lawsuit

Xencor Outlicenses Autoimmune Disease Candidate To Zenas BioPharma ↗

November 22, 2021

Zenas BioPharma has acquired from Xencor Inc (NASDAQ: XNCR) exclusive worldwide rights to develop, manufacture, and commercialize obexelimab. Obexelimab is a...

Via Benzinga

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

November 21, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Present at Upcoming Investor Conferences

November 19, 2021

From Xencor, Inc.

Via Business Wire

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

November 12, 2021

From Xencor, Inc.

Via Business Wire

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting

November 12, 2021

From Xencor, Inc.

Via Business Wire

Novartis Dumps Another Bispecific Candidate From Xencor Deal ↗

November 09, 2021

Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The...

Via Benzinga

Xencor, inc (XNCR) Q3 2021 Earnings Call Transcript ↗

November 08, 2021

XNCR earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306

November 08, 2021

From Xencor, Inc.

Via Business Wire

Preview: Xencor's Earnings ↗

November 05, 2021

Xencor (NASDAQ:XNCR) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting

November 04, 2021

From Xencor, Inc.

Via Business Wire

Earnings Scheduled For November 8, 2021 ↗

November 08, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...

Via Benzinga

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

November 03, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Present at Upcoming Investor Conferences

November 02, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021

November 01, 2021

From Xencor, Inc.

Via Business Wire

JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody ↗

October 04, 2021

Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global...

Via Benzinga

Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies

October 04, 2021

From Xencor, Inc.

Via Business Wire

Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting

October 01, 2021

From Xencor, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.